Glucose metabolism-based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Zilong,Bai

第一单位： Department of Surgical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China.

作者： Zilong,Bai ^[1] ; Chunyu,Yan ^[2] ; Yuanhua,Nie ^[1] ; Qingnuo,Zeng ^[1] ; Longwen,Xu ^[1] ; Shilong,Wang ^[1] ; Dongmin,Chang ^[1]

作者单位： Department of Surgical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China. ^[1] Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China. ^[2]

关键词 colon adenocarcinoma (COAD)glucose metabolism immunotherapy metabolic reprogramming prognostic signature

主题词人类(Humans);结肠肿瘤(Colonic Neoplasms);腺癌(Adenocarcinoma);免疫疗法(Immunotherapy);碳水化合物代谢(Carbohydrate Metabolism);葡萄糖(Glucose)

DOI 10.1002/jgm.3620

PMID 37973153

发布时间 2024-01-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交